Clinical Trials
688 trialsFollow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
National Institutes of Health Clinical Center (CC)
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
National Institutes of Health Clinical Center (CC)
MRgFLA
University Health Network, Toronto
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
AtezoCab
University of Utah
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
Columbia University
MOB-RT
University Health Network, Toronto
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Janssen Research & Development, LLC
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MEVPRO-3
Pfizer
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
OBSAPA
Janssen Cilag S.A.S.
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
University of California, San Francisco
BCB RIV
Institut du Cancer de Montpellier - Val d'Aurelle
DIRECT
University Health Network, Toronto
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
AMX-500
Vir Biotechnology, Inc.
Solar-Stage
Curium US LLC
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.
TransPRIDE
Queen Mary University of London
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Amgen
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
TERPS Trial for de Novo Oligometastic Prostate Cancer
University of Maryland, Baltimore
P-GAP
University of Alberta
CREATINE-52
University of Utah
MK-5684-004
Merck Sharp & Dohme LLC
GREENS
University of Southern California
OMNIRAY
Eli Lilly and Company
CUIMC Focal Therapy Registry
Columbia University
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
CERTIS1
AstraZeneca
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
M.D. Anderson Cancer Center
PragMet
University of Colorado, Denver
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
PREDICT
Alliance for Clinical Trials in Oncology
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Collection of Blood From Patients With Cancer
National Institutes of Health Clinical Center (CC)
Collection of Blood From Patients With Prostate Cancer
National Institutes of Health Clinical Center (CC)
uTRACE-101
Curasight
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Novartis
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
DP-04
AstraZeneca
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
A Phase I Trial of A-CAR032 in Participants With mCRPC
Shanghai AbelZeta Ltd.
INSPIRE: INnovative SABR for Prostate Cancer All IREland
Cancer Trials Ireland